Need proof that CV outcomes are make-or-break? See Merck's reaction to anacetrapib trial win

28th June 2017 Uncategorised 0

Merck & Co.’s cholesterol-fighting candidate anacetrapib pulled off a surprise win in its cardiovascular outcomes trial. But did it win big? The details aren’t available yet, but analysts wonder whether the data will be impressive enough to make a launch worth the trouble.

More: Need proof that CV outcomes are make-or-break? See Merck's reaction to anacetrapib trial win
Source: fierce